DK0643608T3 - Proteinrensning - Google Patents

Proteinrensning

Info

Publication number
DK0643608T3
DK0643608T3 DK93908538T DK93908538T DK0643608T3 DK 0643608 T3 DK0643608 T3 DK 0643608T3 DK 93908538 T DK93908538 T DK 93908538T DK 93908538 T DK93908538 T DK 93908538T DK 0643608 T3 DK0643608 T3 DK 0643608T3
Authority
DK
Denmark
Prior art keywords
protein purification
purification
application
relates
receptor proteins
Prior art date
Application number
DK93908538T
Other languages
Danish (da)
English (en)
Inventor
Gail Folena-Wasserman
John H O'grady
Thomas M Smith
John Lifter
Original Assignee
Avant Immunotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avant Immunotherapeutics Inc filed Critical Avant Immunotherapeutics Inc
Application granted granted Critical
Publication of DK0643608T3 publication Critical patent/DK0643608T3/da

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B01D15/1871—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/34—Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK93908538T 1992-03-24 1993-03-24 Proteinrensning DK0643608T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/857,022 US5252216A (en) 1992-03-24 1992-03-24 Protein purification
PCT/US1993/002732 WO1993018835A1 (fr) 1992-03-24 1993-03-24 Purification de proteines

Publications (1)

Publication Number Publication Date
DK0643608T3 true DK0643608T3 (da) 2000-10-02

Family

ID=25324998

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93908538T DK0643608T3 (da) 1992-03-24 1993-03-24 Proteinrensning

Country Status (19)

Country Link
US (1) US5252216A (fr)
EP (1) EP0643608B1 (fr)
JP (1) JP3335629B2 (fr)
KR (1) KR100241172B1 (fr)
AT (1) ATE193839T1 (fr)
AU (1) AU659936B2 (fr)
CA (1) CA2132533C (fr)
DE (1) DE69328864T2 (fr)
DK (1) DK0643608T3 (fr)
ES (1) ES2149206T3 (fr)
FI (1) FI109202B (fr)
GR (1) GR3034332T3 (fr)
MX (1) MX9301655A (fr)
NO (1) NO310855B1 (fr)
NZ (1) NZ251601A (fr)
PT (1) PT643608E (fr)
TW (1) TW321651B (fr)
WO (1) WO1993018835A1 (fr)
ZA (1) ZA932015B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395888B1 (en) * 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
DE4331358A1 (de) * 1992-10-12 1994-04-14 Braun Melsungen Ag Verfahren zur quantitativen selektiven Entfernung oder präparativen Gewinnung von Tumor-Nekrose-Faktor (TNF) oder/und Lipopolysacchariden (LPS) aus wäßrigen Flüssigkeiten
CN1130353A (zh) * 1993-07-09 1996-09-04 史密丝克莱恩比彻姆公司 蛋白质的纯化
US5679546A (en) * 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
DE19549420A1 (de) * 1995-04-27 1997-09-18 Braun Melsungen Ag Verfahren zur simultanen extrakorporalen Elimination von Tumor-Nekrose Faktor alpha (TNF alpha) und bakteriellen Lipopolysacchariden (LPS) aus Vollblut oder/und Blutplasma
DE69627333T2 (de) * 1995-06-26 2004-02-12 PerSeptive Biosystems, Inc., Framingham Automatisierte, kontinuierliche mehrdimensionale hochgeschwindigkeitsmolekularselektion und -analyse
EP1300679A3 (fr) * 1995-06-26 2004-04-14 Perseptive Biosystems, Inc. Sélection et analyse moléculaire
GB9515196D0 (en) * 1995-07-25 1995-09-20 Matthey Rustenburg Refines Interseparation of platignum group metals
CA2294749C (fr) * 1997-06-27 2007-01-02 Life Technologies, Inc. Dispositif et procede de concentration et purification de molecules biologiques en une etape
US5993653C1 (en) * 1997-08-11 2001-11-06 Phenomenex Composition and column used in hplc
US6869796B2 (en) * 1997-08-26 2005-03-22 Avaris Ab Method of introducing organic molecules into target cells
US20070122904A1 (en) * 2000-09-29 2007-05-31 Unisearch Limited Method and apparatus for culturing cells
US6855263B2 (en) * 2002-07-23 2005-02-15 Nuvue Technologies, Inc. Rapid process for purification and concentration of plasmin
DE10255508A1 (de) * 2002-11-27 2004-06-17 Forschungszentrum Jülich GmbH Verfahren zur Kultivierung von Zellen zur Produktion von Substanzen
US6913695B2 (en) * 2003-07-08 2005-07-05 Bayer Healthcare Llc Sanitization of chromatographic media
WO2005012349A2 (fr) * 2003-08-01 2005-02-10 Lorantis Limited Processus
US7329353B2 (en) * 2004-01-23 2008-02-12 Amgen Inc. LC/MS method of analyzing high molecular weight proteins
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
PL1787126T3 (pl) * 2004-07-20 2010-03-31 Symphogen As Sposób charakteryzowania poliklonalnej linii komórkowej
WO2006011580A1 (fr) * 2004-07-27 2006-02-02 Genomidea, Inc. Procédé de purification d'une enveloppe de virus
EP1789454B1 (fr) * 2004-08-12 2017-07-05 Lipoxen Technologies Limited Fractionnement de polysaccharide chargé
EP1738763A1 (fr) 2005-06-30 2007-01-03 AVANT Immunotherapeutics, Inc. Utilisation de proteines d'inhibition du système complémentaire pour le traitement d'und lesion de la moelle épinière
WO2007053235A1 (fr) * 2005-11-04 2007-05-10 Sachem, Inc. Processus chromatographie par deplacement a echange de cations et composes cationiques organiques servant de composes deplaceurs dans un tel processus
EP2596807B1 (fr) 2006-03-08 2015-12-16 Archemix LLC Aptamères de liaison complémentaires et agents anti-C5 utiles dans le traitement des troubles oculaires
WO2010101865A1 (fr) 2009-03-02 2010-09-10 Zymo Research Corporation Colonne universelle
CN104928336B (zh) 2009-10-26 2020-05-08 弗·哈夫曼-拉罗切有限公司 用于生产糖基化免疫球蛋白的方法
CN103237557A (zh) 2010-09-15 2013-08-07 赛尔戴克斯治疗公司 用可溶性I型补体受体(sCR1)治疗慢性肾病
US8895291B2 (en) 2010-10-08 2014-11-25 Terumo Bct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
EP2632476B1 (fr) 2010-10-27 2017-06-14 Celldex Therapeutics, Inc. Méthode pour améliorer la fonction de transplantation à l'aide d'un récepteur de complément soluble de type 1 (scr1)
WO2016049421A1 (fr) 2014-09-26 2016-03-31 Terumo Bct, Inc. Alimentation programmée
WO2017205667A1 (fr) 2016-05-25 2017-11-30 Terumo Bct, Inc. Expansion cellulaire
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
WO2018184028A2 (fr) 2017-03-31 2018-10-04 Terumo Bct, Inc. Expansion cellulaire
KR20250026267A (ko) * 2022-06-17 2025-02-25 씨에스엘 이노베이션 피티와이 엘티디 가용성 보체 수용체 및 이의 변이체의 정제

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2319495C2 (de) * 1973-04-17 1985-01-10 Yeda Research And Development Co., Ltd., Rehovot Verfahren zum selektiven, reversiblen Binden von Biomolekülen an ein Adsorbens in einer chromatographischen Säule
US4000098A (en) * 1974-08-16 1976-12-28 Palo Alto Medical Research Foundation Separation of proteins by hydrophobic adsorption
DE3149360A1 (de) * 1981-12-12 1983-06-16 Biotest-Serum-Institut Gmbh, 6000 Frankfurt "verfahren zur reinigung und/oder phytohaemagglutinin-abtrennung von human-interleukin-2"
US4920196A (en) * 1982-07-30 1990-04-24 Genentech, Inc. Human lymphotoxin
US4908434A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Process for preparing purified interleukin-2
US4743680A (en) * 1985-02-01 1988-05-10 New York University Method for purifying antihemophilic factor
US4894439A (en) * 1986-05-22 1990-01-16 Cetus Corporation N-terminal derivatives of tumor necrosis factor purified by microporous PTFE membranes
AU597924B2 (en) * 1985-12-11 1990-06-14 Natinco Nv Solubilization of protein aggregates
US4770781A (en) * 1986-03-03 1988-09-13 Merck & Co., Inc. Purification of human interleukin-1 species
US4771128A (en) * 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
AU609824B2 (en) * 1987-06-15 1991-05-09 Southern Cross Biotech Pty Ltd. Production of proteins in active forms
US4981799A (en) * 1987-08-21 1991-01-01 Takeda Chemical Industries, Ltd. Acylamino acid racemase, production and use thereof
US4765903A (en) * 1987-10-06 1988-08-23 Interferon Sciences, Inc. Purification of monomeric interferon
US5159063A (en) * 1989-02-02 1992-10-27 The United States Of America As Represented By The Department Of Health And Human Services Isolation and characterization of a 120 kda glycoprotein plasma
US5030352A (en) * 1990-01-25 1991-07-09 Purdue Research Foundation Coated media for chromatography

Also Published As

Publication number Publication date
AU3932493A (en) 1993-10-21
FI944412L (fi) 1994-09-23
EP0643608B1 (fr) 2000-06-14
ES2149206T3 (es) 2000-11-01
MX9301655A (es) 1994-03-31
NO310855B1 (no) 2001-09-10
ATE193839T1 (de) 2000-06-15
TW321651B (fr) 1997-12-01
DE69328864T2 (de) 2000-12-14
CA2132533C (fr) 2004-01-13
FI109202B (fi) 2002-06-14
GR3034332T3 (en) 2000-12-29
US5252216A (en) 1993-10-12
WO1993018835A1 (fr) 1993-09-30
AU659936B2 (en) 1995-06-01
DE69328864D1 (de) 2000-07-20
NZ251601A (en) 1997-03-24
KR950700779A (ko) 1995-02-20
PT643608E (pt) 2000-11-30
ZA932015B (en) 1994-09-21
CA2132533A1 (fr) 1993-09-30
FI944412A0 (fi) 1994-09-23
JP3335629B2 (ja) 2002-10-21
NO943546D0 (no) 1994-09-23
JPH07505469A (ja) 1995-06-15
KR100241172B1 (ko) 2000-02-01
EP0643608A4 (fr) 1997-11-26
NO943546L (no) 1994-11-23
EP0643608A1 (fr) 1995-03-22

Similar Documents

Publication Publication Date Title
NO943546D0 (no) Proteinrensing
DK0746398T3 (da) Antistofrensning
BR9808934A (pt) Proteìnas de fusão de região constante de receptor/imunoglobulina tgf-beta do tipo ii
DK672788A (da) Rekombinant-dna-vektorer til direkte udtrykkelse af aktiveret humant protein c
DE69430016D1 (de) Proteinreinigung
DK0538754T3 (da) Anvendelse af antistofholdige præparater til immunundertrykkelse
FI904851A0 (fi) Radiomaerkta antikoagulantpeptider.
DE69032258D1 (de) Antikoagulierende Peptide
ITRM920658A0 (it) Procedimento per la purificazione della proteina endotelina
ATE177432T1 (de) Antikoagulierende peptide
DE69122103D1 (de) Antigerinnungspeptide
FI924835L (fi) Pectinatus-bakteerin proteiinifragmentteja
IT8921396A0 (it) Procedimento per la sintesi di peptidi preventivamente identificati come siti di interazione di proteine interagenti.